Wize Pharma licenses Copernicus’ gene therapy technology

Wize Pharma has entered into an exclusive license agreement to develop and commercialize products based on non-viral gene therapy technology from Copernicus Therapeutics, the company announced in a press release.
WP-REP1, Wize’s gene therapy product based on Copernicus’ technology, will be comprised of DNA compromised nanoparticles and designed to treat choroideremia. It will be administered via intraocular injection and provide a functioning CHM gene to photoreceptors and retinal pigment epithelial cells.
“We are very pleased and excited to enter into this agreement with

Full Story →